RxDoctor Payments Data

John Milner, PA

Physician Assistant · Sacramento, CANPI 1558026021

Payments from drug & device makers

$2,129in general payments, 2019–2025

Across 81 payments — averaging $26.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$361
  • Sanofi$314
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$270
  • AbbVie$245
  • Madrigal Pharmaceuticals$187
  • Takeda Pharmaceuticals U.S.A., Inc.$166
  • plus $586 from 9 others

What the payments were for

  • Food & beverage$2,04596%
  • Education$844%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,129 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$52,961
Medicare patients
368
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide122$109,947
XifaxanRifaximin24$80,227
CreonLipase/Protease/Amylase11$38,165
VemlidyTenofovir Alafenamide19$29,591
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates360$23,983
TrulancePlecanatide22$19,382
Mesalamine26$10,241
Sucralfate33$4,370
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C16$2,178
Famotidine160$1,657
Omeprazole158$1,537
Pantoprazole Sodium141$1,475
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl96$1,376
Dicyclomine Hcl50$1,308
Esomeprazole Magnesium24$632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$245$148,112133 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$270$101,78762 claims
GileadVemlidy$361$29,59119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →